Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers ...
The clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts ...
At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors ...
What's possible when AI models can learn from additional health data modalities to create a more complete understanding of ...
In an interview with Stephen Onikoro, chief operating officer of PharmaForceIQ, he shared that pharma marketers can’t pour ...
Results published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for ...
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after ...
Though its data could be useful for pharmaceutical firms, Polansky’s latest entrepreneurial endeavor, Outer Bio, is serious ...
Not only is the XBI continuing to hover around a historic high, but drug companies can’t seem to get enough of both large IPOs and big-ticket M&A.
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning ...
After peaking in 2024, venture investments in startups involved in the space declined last year. But a broader adoption of AI ...
The results erased more than $1 billion in market value and raised questions about how impactful drugs that block the TL1A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results